Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

panobinostat

Specified dose on specified days

DRUG

carfilzomib

Specified dose on specified days

Trial Locations (13)

32503

Woodlands Medical Specialists, Pensacola

33705

Florida Cancer Specialists North, St. Petersburg

33916

Florida Cancer Specialists South, Fort Myers

37205

Tennessee Oncology, Nashville

37404

Tennessee Oncology-Chattanooga, Chattanooga

45242

Oncology Hematology Care, Inc., Cincinnati

47802

Providence Medical Group, Terre Haute

RHHP/Hope Cancer Center, Terre Haute

64132

Research Medical Center, Kansas City

73505

Cancer Centers of Southwest Oklahoma, Lawton

76104

The Center for Cancer and Blood Disorders, Fort Worth

80218

Colorado Blood Cancer Institute, Denver

07962

Hematology-Oncology Associates - Northern NJ, Morristown

Sponsors
All Listed Sponsors
collaborator

Onyx Therapeutics, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER